A1 Journal article – refereed

Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment




List of Authors: Xu Xiaoyu, Liu Chang, Wang Yonghui, Koivisto Oliver, Zhou Junnian, Shu Yilai, Zhang Hongbo

Publisher: Elsevier B.V.

Publication year: 2021

Journal: Advanced Drug Delivery Reviews

Journal name in source: Advanced Drug Delivery Reviews

Volume number: 176

eISSN: 1872-8294

DOI: http://dx.doi.org/10.1016/j.addr.2021.113891

URL: https://www.sciencedirect.com/science/article/pii/S0169409X21002830?via%3Dihub


Abstract

CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by CRISPR/Cas9 are established. However, significant challenges remain for its clinical applications. The greatest challenge for CRISPR/Cas9 therapy is how to safely and efficiently deliver it to target sites in vivo. Nanotechnology has greatly contributed to cancer drug delivery. Here, we present the action mechanisms of CRISPR/Cas9, its application in cancer therapy and especially focus on the nanotechnology-based delivery of CRISPR/Cas9 for cancer gene editing and immunotherapy to pave the way for its clinical translation. We detail the difficult barriers for CRISIR/Cas9 delivery in vivo and discuss the relative solutions for encapsulation, target delivery, controlled release, cellular internalization, and endosomal escape.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2021-10-09 at 09:24